New Millennium Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

New Millennium Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4.6K	Hold	200	–	–	﹤0.01%	254
2025 Q3	$6.02K	Hold	200	–	–	﹤0.01%	253
2025 Q2	$7.27K	Hold	200	–	–	﹤0.01%	221
2025 Q1	$7.24K	Hold	200	–	–	﹤0.01%	233
2024 Q4	$8.41K	Hold	200	–	–	﹤0.01%	244
2024 Q3	$11.1K	Hold	200	–	–	0.01%	173
2024 Q2	$8.22K	Buy	+200	New	+$8.54K	0.01%	199
2024 Q1	–	Sell	-200	Closed	-$9.56K	–	320
2023 Q4	$9.56K	Hold	200	–	–	0.01%	206
2023 Q3	$7.13K	Hold	200	–	–	0.01%	190
2023 Q2	$9.23K	Hold	200	–	–	0.01%	175
2023 Q1	$8.02K	Hold	200	–	–	0.01%	203
2022 Q4	$9.27K	Hold	200	–	–	0.01%	200
2022 Q3	$8K	Buy	+200	New	+$10.3K	0.01%	209

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

New Millennium Group's RARE Position: Q4 2025 in Review

New Millennium Group held its Ultragenyx Pharmaceutical (RARE) position steady in Q4 2025 at 200 shares worth $4.6K. The position accounts for ﹤0.01% of the portfolio, ranked #254.

New Millennium Group first reported a position in RARE in Q3 2022 and has held it in 13 quarters since. The position peaked at $11.1K in Q3 2024. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

New Millennium Group held 200 shares of Ultragenyx Pharmaceutical worth $4.6K as of Q4 2025.
New Millennium Group left its Ultragenyx Pharmaceutical share count unchanged in Q4 2025.
Ultragenyx Pharmaceutical made up ﹤0.01% of New Millennium Group's portfolio in Q4 2025, its #254 holding.
New Millennium Group first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and has held it in 13 quarters since.
New Millennium Group's Ultragenyx Pharmaceutical position peaked at $11.1K in Q3 2024.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.